タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	最新高血圧診療学
出版社	永井書店
発行日	2010-08-01
著者	今泉勉(編集)
ISBN	9784815918682
ページ数	353
版刷巻号	第1版
分野	臨床医学：内科血管
閲覧制限	未契約

2009年発表の「日本高血圧治療ガイドライン」を作成した担当者によるテキスト。血圧はどのように調整されているのか、高血圧・臓器障害をどのように診察・診断・治療するのかなどについて解説。

目次

表紙
閲覧
執筆者一覧
閲覧
序文
閲覧
目次
閲覧
I. 総論
P.1閲覧
- 1. 高血圧とは
- 2. わが国における高血圧の疫学と動向
- 3. JSH 2009と各国の高血圧治療ガイドライン
- 4. 大規模臨床試験の意義と限界
II. 血圧はどのように調節されているのかどうして高血圧になるのか
P.29閲覧
- 1. 中枢神経系・自律神経系調節
- 2. 血管内皮機能
- 3. 腎・体液性調節
- 4. 血行力学
- 5. 内分泌系・血管作動物質(レニン・アンジオテンシン系を含む)
- 6. 遺伝子、遺伝子多型
III. 高血圧・臓器障害をどのように診察し診断するのか
P.75閲覧
- 1. 高血圧症の診断基準
- 2. 外来診察室での血圧の測り方、診察の仕方
- 3. 24時間自由行動下血圧測定(ABPM)、家庭血圧の測り方、活用法
- 4. 高血圧管理計画の立て方
- 5. 二次性高血圧の見分け方
- 6. 臓器障害をどう評価するのか
IV. 高血圧をどう治療するか
P.153閲覧
- 1. 生活習慣の改善
- 2. 薬物療法
- 3. 合併症を伴った高血圧の治療
- 4. 二次性高血圧症の治療
- 5. 高齢者高血圧症
- 6. 女性の高血圧症
- 7. 白衣高血圧・仮面高血圧・早朝高血圧・職場高血圧
- 8. 一過性の血圧上昇(高血圧緊急症・周術期高血圧など)
- 9. 難治性 / 治療抵抗性高血圧
V. これからの高血圧治療
P.305閲覧
- 1. Pre-hypertension(正常高値血圧)から治療する?
- 2. テーラーメイド医療
- 3. 新しい降圧薬レニン阻害薬
- 4. 特定健診・特定保健指導
- 5. 高血圧(検査・治療)の費用対効果
索引
閲覧
奥付
閲覧

参考文献

I. 総論

P.6 掲載の参考文献

1) Oliver WJ, Cohen EL, Neel JV:Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a " no salt " culture. Circulation 52:146-151, 1975.
pubmed

2) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 7:51-183, 1999.

3) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2000. ライフサイエンス出版, 東京, 2000.

4) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2004. ライフサイエンス出版, 東京, 2004.

5) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

6) Chobanian AV, Bakris GL, Black HR, et al:National High Blood Pressure Education Program Coordinating Committee; Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003.
pubmed

7) 厚生統計協会:国民衛生の動向; 死亡数.率. pp382-383, 2007.

P.11 掲載の参考文献

1) Ueshima H:Explanation for the Japanese paradox; Prevention of increase in coronary heart diseases and reduction in stroke. J Atheroscler Tromb 14:278-286, 2007.

2) Kubo M, Kiyohara Y, Kato l, et al:Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community; the Hisayama study. Stroke 34:2349-2354, 2003.

3) Kitamura A, Iso H, Iida M, et al:Trends in the indicence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med 112:104-109, 2002.

4) 循環器病予防研究会:第5次循環器疾患基礎調査結果. 中央法規出版, 東京, 2002.

5) Intersalt Cooperative Research Group:Intersalt; an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 297:319-328, 1988.

6) Sasaki N:High blood pressure and the salt intake of the Japanese. Japan Heart J 3:313-324, 1962.

7) 上島弘嗣:わが国の循環器疾患とその危険因子の動向. NIPPON DATAからみた循環器疾患のエビデンス, 上島弘嗣 (編著), pp3-13, 日本医事新報, 東京, 2008.

8) 厚生労働省:平成17年国民栄養調査結果の概要. http://www.mhlw.go.jp/houdou/2007/05/h0516-3.html (2009 年6月10日アクセス)

9) 上島弘嗣:高血圧の疫学. NIPPON DATAからみた循環器疾患のエビデンス, 上島弘嗣 (編著), pp14-20, 日本医事新報, 東京, 2008.

10) Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group:Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet (DASH-Sodium Collaborative Research Group). N Engl J Med 344:3-10, 2001.

11) 上島弘嗣:生活習慣の改善による高血圧の予防と治療. NIPPON DATA からみた循環器疾患のエビデンス, 上島弘嗣 (編著), pp21-27, 日本医事新報, 東京, 2008.

12) 厚生省公衆衛生局:昭和55年循環器疾患基礎調査報告. 日本心臓財団, 東京, 1982.

13) 厚生省公衆衛生局:第4次循環器疾患基礎調査 (平成2年) 報告. 循環器病振興財団および日本循環器病研究管理協議会, 東京, 1993.

14) Asia Pacific Cohort Studies Collaboration:Blood pressure and cardiovascular disease in the Asia pacific region. J Hypertens 21:707-716, 2003.

15) Okayama A, Kadowaki T, Okamura T, et al; The NIPPON DATA80 Research Group:Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80). J Hypertens 24:459-462, 2006.

16) Murakami Y, Hozawa A, Okamura T, et al:The Evidence for Cardiovascular Prevention from Observational Cohorts in Japan Research Group (EPOCH-Japan). Hypertension 51:1483-1491, 2008.

17) 健康体力づくり財団:健康日21. http://www.kenkounippon21.gr.jp/kenkounippon21/about/index.html

18) 常松典子, 上島弘嗣, 奥田奈賀子, ほか; INTERMAP日本研究班; 減塩食実施者は通常の食生活の人に比べ食塩摂取量がどの程度少ないか? 日循予防誌 39:149-155, 2004.

P.19 掲載の参考文献

1) Guideline Committee 2003:European Society of Hypertension-European Society of Cardiology guideline for the management of arterial hypertension (ESH-ESC 2003). J Hypertens 21:1011-1053, 2003.

2) Guideline Committee 2007:European Society of Hypertension-European Society of Cardiology guideline for the management of arterial hypertension (ESH-ESC 2007). J Hypertens 25:1005-1087, 2007.

3) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

4) Whitworth JA; World Health Organization, International Society of Hypertension Writing Group:2003 World Health Organization, International Society of Hypertension. J Hypertens 21:1983-1992, 2003.
pubmed

5) Chobanian AV, Bakris GL Black HR, et al:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; the JNC 7 report. JAMA 289:2560-2572, 2003.
pubmed

6) Khan NA, Hemmelgarn B, Herman RJ, et al:The 2008 Canadian hypertension education program recommendations for the management of hypertension; part 2.therapy. Can J Cardiol 24:465-475, 2008.
pubmed

7) Dahlof B, Devereux RB, Kjeldsen SE, et al:Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE); a randomized trial against atenolol. Lancet 359:995-1003, 2002.
pubmed

8) Dahlof B, Sever PS, Poulter NR, et al:Prevention of cardiovascular events with an anti-hypertensive regimen of amolodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA); a multicentre randomized controlled trial. Lancet 366:895-906, 2005.

9) Berl T, Hunsicker LG, Lewis JB, et al:Cardiovascular outcomes in the irbesartan diabetic Nephropathy trial of patients with type 2 diabetes and overt nephropathy. Arch Intern Med 138:542-549, 2003.

10) Casas JP, Chua W, Loukogeorgakis S, et al:Effect of inhibitors of the rennin-angiotensin system and other anti-hypertensive drugs on renal outcomes; systematic review and metaanalysis. Lancet 366:2026-2033, 2005.

11) Hasebe N, Kikuchi K, NICE-Combi study group:Controlled release nifedipine And candesartan low dose combination therapy in patients with essential hypertension; The NICE Combi (Nifedipine and Candesartan Combination) study. J Hypertens 23:445-453, 2005.

12) Ogawa S, Takeuchi K, Mori T, et al:Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 30:325-334, 2007.

13) Desertori M, Latini R, Barlera S, et al:Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606-1617, 2009.

14) Tanabe Y, Kawamura Y, Sakamoto N, et al:Blood pressure control and reduction of left atrial overload is essential for controlling atrial fibrillation. Int Heart J 50:445-456, 2009.
pubmed

15) Turnbull F, Neal B, Pfeffer M, et al:Blood pressure dependent and independent effects of agents that inhibits the renin-angiotensin system. J Hypertens 25:951-958, 2007.
pubmed

P.28 掲載の参考文献

1) Mancia G:Role of outcome trials in providing information on antihypertensive treatment; importance and limitations. Am J Hypertens 19:1-7, 2006.

2) Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events; results of prospectively-designed overviews of randomized trials. Lancet 362:1527-1535, 2003.
pubmed

3) Turnbull F, Woodward M, Neal B, et al:Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 29:2669-2680, 2008.
pubmed

4) Blood Pressure Lowering Treatment Trialists:Collaboration:Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults; mata-analysis of randomized trials. BMJ 336:1121-1123, 2008.

5) 築山久一郎:大規模臨床試験からみた降圧薬併用の評価. Ther Res 30:1019-1047, 2009.
Medical*Online

6) Tocci G, Sciarretta S, Volpe M:Development of heart failure in recent hypertension trials. J Hypertens 26:1477-1486, 2008.
pubmed

7) Kunz R, Friedrich C, Wolbers M, et al:Meta-analysis; Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30-48, 2008.
pubmed

8) Tu K, Mamdani MM, Jacka RM, et al:The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 168:553-557, 2003.
pubmed

9) Pilote L:Ramipril use in Canada; HOPE or HYPE? CMAJ 168:568-569, 2003.
pubmed

10) Wang TJ, Ausiello JC, Stafford RS:Trends in antihypertensive drug advertising, 1985-1996. Circulation 99:2055-2057, 1999.
pubmed

11) Santiago MG, Bucher HC, Nordmann AJ:Accuracy of drug advertisements in medical journals under new law regulating the marketing of pharmaceutical products in Switzerland. BMC Med Informat Decision Makung 2008; 8:61 (Electric resource:http://biomedcentral.com/1472-6947/8/61

12) Kostis JB, Wilson AC, Freudenberger RS, et al:Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95:29-35, 2005.

13) Costanzo P, Perrone-Filardi P, et al:Calcium channel blockers and cardiovascular outcomes; ameta-analysis of 175 634 patients. J Hypertens 27:1136-1151, 2009.

14) Chapman N, Chang CL, Dahlof B, et al:Effects of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 118:42-48, 2008.

15) Greving JP, Denig P, de Zeeuw D, et al:Claims in advertisements for antihypertensive drugs in a Dutch medical journal. J Hypertens 25:713-722, 2007.

II. 血圧はどのように調節されているのかどうして高血圧になるのか

P.37 掲載の参考文献

1) 廣岡良隆,砂川賢二:中枢神経, 自律神経による心血管機能調節. 循環器科 63:1-6, 2008.

2) Guyenet PG:The sympathetic control of blood pressure. Nat Rev Neurosci 7:335-346, 2006.
pubmed

3) Grassi G:Assessment of sympathetic cardiovascular drive in human hypertension; achievements and perspectives. Hypertension 54:690-697, 2009.
pubmed

4) 高橋伯夫:中枢神経説をめぐって. 高血圧研究の歴史, 日和邦男 (編), pp65-80, 先端医学社, 東京, 2002.

5) Osborn JW, Averina VA, Fink GD:Current computational models do not reveal the importance of the nervous system in long-term control of arterial pressure. Exp Physiol 94:389-396, 2009.

6) Joyner MJ, Charkoudian N, Wallin BG:A sympathetic view of the sympathetic nervous system and human blood pressure regulation. Exp Physiol 93:715-724, 2008.
pubmed

7) Sved AF, Ito S, Sved JC:Brainstem mechanisms of hypertension; role of the rostral ventrolateral medulla. Curr Hyp Rep 5:262-268, 2003.

8) Osborn JW, Jacob F, Guyman P:A neural set point for the long-term control of arterial pressure; beyond the arterial baroreceptor reflex. Am J Physiol Regul Integr Comp Physiol 288:R846-R855, 2005.

9) Hirooka Y:Lozalized gene transfer and its application for the study of central cardiovascular control. Auton Neurosci 126-127:120-129, 2006.

10) Kishi T, Hirooka Y, Kimura Y, et al:Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 109:2357-2362, 2004.
pubmed

11) Hirooka Y:Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. Auton Neurosci 142:20-24, 2008.
pubmed

12) Peterson JR, Sharma RV, Davisson RL:Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hyp Rep 8:232-241, 2006.

13) Nozoe M, Hirooka Y, Koga Y, et al:Inhibition of Rac1-derived reactive oxygen species in nucleus tractus solitarius decreases blood pressure and heart rate in stroke-prone spontaneously hypertensive rats. Hypertension 50:62-68, 2007.
pubmed

14) Nozoe M, Hirooka Y, Koga Y, et al:Mitochondria-derived reactive oxygen species mediate sympathoexcitation induced by angiotensin II in the rostral ventrolateral medulla. J Hypertens 26:2176-2184, 2008.
pubmed

15) Chan SHH, Wu KLH, Chang AYW, et al:Oxidative impairement of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. Hypertension 53:217-227, 2009.
pubmed

16) Kimura Y, Hirooka Y, Sagara Y, et al:Overexpression of inducible nitric oxide synthase in rostral ventrolateral medulla causes hypertension and sympathoexcitation via an increase in oxidative stress. Circ Res 96:252-260, 2005.
pubmed

17) Ito K, Hirooka Y, Sakai K, et al:Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system; possible involvement in neural mechanisms of hypertension. Circ Res 92:1337-1343, 2003.
pubmed

18) Ito K, Hirooka Y:Role of Rho/Rho-kinase in the brainstem in cardiovascular regulation via the sympathetic nervous system. Sympathetic Nervous System research Developments, Kaneko M (ed), pp93-110, Nova Science Publishers, New York, 2007.

19) Koga Y, Hirooka Y, Araki S, et al:High salt intake enhances blood pressure increase during development of hypertension via oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertens Res 31:2075-2083, 2008.
pubmed

20) Ito K, Hirooka Y, Sunagawa K:Acquisition of brain Na sensitivity contributes to salt-induced sympathoexcitation and cardiac dysfunction in mice with pressure overload. Circ Res 104:1004-1011, 2009.
pubmed

21) Araki S, Hirooka Y, Kishi T, et al:Olmesartan reduces oxidatve stress in the brain of stroke-prove spontaneously hypertensive rats assessed by an in vivo ESR method. Hypertens Res 32:1091-1096, 2009.

22) Konno S, Hirooka Y, Kishi T, et al:Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prove spontaneously hypertensive rats. J Cardiovasc Pharmacol 52:555-560, 2008.

23) Krum H, Walton A, Sievert H, et al:Catheter-based renal sympathetic denervation for resistant hypertension; a multicentre safety and proof-of-principle cohort study. Lancet 373:1275-1281, 2009.
pubmed

24) Wustmann K, Kucera JP, Scheffers 1, et al:Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant hypertension. Hypertension 54:530-536, 2009.
pubmed

25) 廣岡良隆:ストレスと心血管リスクの機序; 交感神経.圧受容器感受性. 循環器科 66:182-188, 2009.

P.45 掲載の参考文献

1) Vanhoutte PM:Endothelium and control of vascular function. Hypertension 13:658-667, 1989.
pubmed

2) Higashi Y, et al:Oxidative stress and endothelial function in cardiovascular diseases (review). Circ J 73:411-418, 2009.
pubmed

3) Huang PL, et al:Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242, 1995.
pubmed

4) Ushio-Fukai M, et al:p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271:23317-23321, 1996.

5) Nakazono K, et al:Does superoxide underlie the pathogenesis of hypertension? Pros Natl Acad Sci 88:10045-10048, 1991.

6) Rajagopalan S, et al:Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation; contribution to alterations of vasomotor tone. J Clin Invest 97:1916-1923, 1996.

7) Duffy SJ, et al:Treatment of hypertension with ascorbic acid. Lancet 354:2048, 1999.
pubmed

8) Higashi Y, et al:Exercise and endothelial function; role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients (review). Pharmacology and Therapeutics 102:87-96, 2004.
pubmed

9) Higashi Y, et al:Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 346:1954-1962, 2002.
pubmed

10) Rao GN, Berk BC:Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 70:593-599, 1992.
pubmed

11) Brasier AR, Recinos A, Eledrisi MS:Vascular inflammation and the renin angiotensin system. Arterioscler Thromb Vasc Biol 22:1257-1266, 2002.
pubmed

12) Pueyo ME, Gonzalez W, Nicoletti A, et al:Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via NF-κB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20:645-651, 2000.

13) Torti SV, Akimoto H, Lin K, et al:Selective inhibition of muscle gene expression by oxidative stress in cardiac cells. J Mol Cell Cardiol 30:1173-1180, 1998.

14) Peng M, Huang L, Xie ZJ, et al:Oxidant-induced activation of nuclear factor-kappa B and activator protein-1 in cardiac myocytes. Cell Mol Biol Res 41:189-197, 1995.
pubmed

15) Shimokawa H, Takeshita A:Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25:1767-1775, 2005.
pubmed

16) Uehata M, et al:Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990-994, 1997.
pubmed

17) Funakoshi Y, et al:Rho-kinase mediated angiotensin-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 38:100-104, 2001.
pubmed

18) Noma K, Oyama N, Liao JK:Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 290:C661-C668, 2006.
pubmed

19) Kobayashi N, et al:Involvement of Rho-kinase pathway for Ang II-induced plasminogen activator inhibitor gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Ther 301:459-466, 2002.
pubmed

P.51 掲載の参考文献

1) Guyton AC:Arterial pressure and hypertension. Circulatory Phisiology III, WB Saunders, Philadelphia, 1980.

2) Cowley AW Jr, et al:Role of the renal medulla in volume and arterial pressure regulation. Am J Phisiol 273:R1-R15, 1997.

3) Ito S, et al:An in vitro approach to the study of macula densa-mediated glomerular hemodynamics. Kidney Int 38:1206-1210, 1990.

4) Keller G, et al:Nephron number in patients with primary hypertension. N Engl J Med 348:101-108, 2003.
pubmed

5) Denton D, et al:The effect of increased salt intake on blood pressure of chimpanzees. Nat Med 1:1009-1016, 1995.
pubmed

6) Hall JE, et al:Anjiotensin II and long-term arterial blood pressure regulation. J Am Soc Nephrol 10:s258-s265, 1999.

7) Kimura G, et al:Intrarenal hemodynamics in patients with essential hypertension. Circ Res 69:421-428, 1991.
pubmed

P.57 掲載の参考文献

1) Kaplan NM:Clinical Hypertension. 9th ed, Williams & Wilkins, Baltimore, 2006.

2) Guyton AC:Kidneys and fluids in pressure regulation. Small volume but large pressure changes. Hypertension 19 (1 Suppl):12-18, 1992.

3) Julius S:Transition from high cardiac output to elevated vascular resistance in hypertension. Am Heart J 116:600-606, 1988.
pubmed

4) Oliver WJ, Cohen EL, Neel JV:Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a " no-salt " culture. Circulation 52:146-151, 1975.
pubmed

5) Denton D, Weisinger R, Mundy Nl, et al:The effect of increased salt intake on blood pressure of chimpanzees. Nat Med 1:1009-1016, 1995.

6) Iwaoka T, Umeda T, Miura F, et al:Renal sodium handling and sodium transport inhibitor in salt-sensitive essential hypertension. J Hypertens 9:49-54, 1991.
pubmed

7) Elkareh J, Kennedy DJ, Yashaswi B, et al:Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 49:215-224, 2007.
pubmed

8) Liu L, Mohammadi K, Aynafshar B, et al:Role of caveolae in signal-transducing function of cardiac Na+/ K+-ATPase. Am J Physiol Cell Physiol 284:C1550-C1560, 2003.
pubmed

9) Guyton AC, Coleman TG, Cowley AV Jr, et al:Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584-594, 1972.
pubmed

10) Brenner BM, Garcia DL, Anderson S:Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1:335-347, 1988.
pubmed

11) Keller G, Zimmer G, Mall G, et al:Nephron number in patients with primary hypertension. N Engl J Med 348:101-108, 2003.
pubmed

12) Sealey JE, Blumenfeld JD, Bell GM, et al:On the renal basis for essential hypertension; nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens 6:763-777, 1988.
pubmed

13) Devereux RB, Laragh JH:Angiotensin converting enzyme inhibition of renin system activity induces reversal of hypertensive target organ changes. Do these effects predict a reduction in long-term morbidity? Am J Hypertens 5:923-926, 1992.
pubmed

14) Julius S, Nesbitt SD, Egan BM, et al:Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685-1697, 2006.
pubmed

15) Julius S, Krause L Schork NJ, et al:Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens 9:77-84, 1991.
pubmed

16) Colombari E, Sato MA, Cravo SL, et al:Role of the medulla oblongata in hypertension. Hypertension 38:549-554, 2001.
pubmed

17) Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al:Neuropeptide Y; a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83:187-195, 1998.
pubmed

18) Ito S, Hiratsuka M, Komatsu K, et al:Ventrolateral medulla AT1 receptors support arterial pressure in Dahl salt-sensitive rats. Hypertension 41:744-750, 2003.
pubmed

19) Yamazato M, Yamazato Y, Sun C, et al:Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 49:926-931, 2007.
pubmed

20) Aalkjaer C, Heagerty AM, Petersen KK, et al:Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation; contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 61:181-186, 1987.
pubmed

21) Heagerty AM, Aalkjaer C, Bund SJ, et al:Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 21:391-397, 1993.
pubmed

22) Cai H, Harrison DG:Endothelial dysfunction in cardiovascular diseases; The role of oxidant stress. Circ Res 87:840-844, 2000.
pubmed

23) Esler M, Straznicky N, Eikelis N, et al:Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48:787-796, 2006.
pubmed

P.65 掲載の参考文献

1) 循環器病の診断と治療に関するガイドライン (1998-1999年度合同研究班報告), 慢性心不全治療ガイドライン. J Circ J 64 (Supple VI):1023-1079, 2000 (2004年度合同研究班報告, 2005年改訂版, pp1-67).

2) Matsubara H:Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83 (12):1182-1191, 1998 Review.
pubmed

3) Matsubara H, Inada M:Molecular insights into angiotensin II type 1 and type 2 receptors; expression, signaling and physiological function and clinical application of its antagonists. Endocr J 45 (2):137-150, 1998 Review.
pubmed

4) Reilly CF, Tewksbury DA, Schechter NM, et al:Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 257 (15):8619-8622, 1982.
pubmed

5) Gammelgaard I, Wamberg S, Bie P:Systemic effects of angiotensin III in conscious dogs during acute double blockade of the renin-angiotensin-aldosterone-system. Acta Physiol (Oxf) 188 (2):129-138, 2006.
pubmed

6) Yanagisawa M, Kurihara H, Kimura S, et al:A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (6163):411-415, 1988.
pubmed

7) Sudoh T, Minamino N, Kangawa K, et al:C-type natriuretic peptide (CNP); a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 168 (2):863-870, 1990.
pubmed

8) Mukoyama M, Nakao K, Hosoda K, et al:Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (4):1402-1412, 1991.
pubmed

9) Yasue H, Yoshimura M, Sumida H, et al:Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1):195-203, 1994.
pubmed

10) Kitamura K, Kangawa K, Kawamoto M, et al:Adrenomedullin; a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 (2):553-560, 1993.
pubmed

P.72 掲載の参考文献

1) Ravogli A, et al:Early 24-hour blood pressure elevation in normotensive subjects with parental hypertension. Hypertension 16:491, 1990.
pubmed

2) Kupper N, Willemsen G, Riese H, et al:Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension 45:80, 2005.

3) Kamide K, Takiuchi S, Miyata T, et al:Single nucleotide polymorphisms analysis of hypertension relating to the effect of antihypertensive drugs? Millennium Genome Project at NCVC. Jpn Heart J 45 (suppl):S69-S93, 2004.

4) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

5) Kato N, et al:High-density association study and nomination of susceptibility genes for hypertension in the Japanese national project. Hum Mol Genet 17:617, 2008.
pubmed

6) The Wellcome Trust Case Control Consortium:Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared control. Nature 447:661, 2007.

7) Jeunemaitre X, et al:Molecular basis of human hypertension; role of angiotensinogen. Cell 71:169, 1992.
pubmed

8) Cambien F, et al:Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641, 1992.
pubmed

9) Higaki J, et al:Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men; the Suita Study. Circulation 101:2060, 2000.
pubmed

10) Agarwal A, et al:Genetics of human hypertension. Trends Endocrinol Metab 16:127, 2005.
pubmed

11) Katsuya T, et al:Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res 26:521, 2003.
pubmed

12) Hunt SC, et al:Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension; trials of hypertension prevention, phase II. Hypertens 32:393, 1998.

III. 高血圧・臓器障害をどのように診察し診断するのか

P.83 掲載の参考文献

1) Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA 273:255-261, 1977.

2) World Health Organization:Arterial Hypertension. Report of a WHO Expert Committee. No. 628, World Health Organization Technical Report Series, Geneva, 1978.

3) Guidelines Subcommittee:1989 guidelines for the management of mild hypertension; memorandum from a WHO/ISH meeting. World Health Organ 67:493-498, 1989.
pubmed

4) Guidelines Subcommittee:1999 World Heaith Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17:151-183, 1999.

5) Levy D, Garrison RJ, Savage DD, et al:Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566, 1990.
pubmed

6) European Society of Hypertension-European Society of Cardiology Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology; guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003.

7) 健康.栄養情報研究会:国民栄養の現状平成18年厚生労働省国民栄養調査結果. 第一出版, 東京, 2009.

8) Ogihara T, Kikuchi K, Matsuoka H, et al:The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32:3-107, 2009.
pubmed

9) Nakamura Y, Yamamoto T, Okamura T, et al:Combined cardiovascular risk factors and outcome; NIPPON DATA80, 1980-1994. Circ J 70:1980-1994, 2006.
pubmed

10) Vasan RS, Larson MG, Leip EP, et al:Impact of high-normal blood pressure on the risk of cardiovascular disease. N Endl J Med 345:1291-1297, 2001.

11) Ohkubo T, Imai Y, Tsuji I, et al:Home blood Pressure measurement has a stronger predictive power for mortality than dose screening blood pressure measurement; a population-based observation in Ohasama, Japan. J Hypertens 16:971-975, 1998.

12) Iimura O:Insulin resistance and hypertension in Japanese. Hypertens Res 19 (Suppl 1) S1-S8, 1996.

13) Ninimiya T, Kiyohara Y, Kubo M, et al:Chronic kidney disease and cardiovascular disease in a general Japanese population; the Hisayama Study. Kidney Int 68:228-236, 2005.

14) Irie F, Iso H, Sairenchi T, et al:The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69:1264-1271, 2006.
pubmed

15) Asayama K, Ohkubo T, Sato A, et al:Proposal of a risk-statification system for the Japanese population based on blood pressure levels; Ohsama study. Hypertns Res 31:1315-1322, 2008.

16) Vasan RS, Larson MG, Leip EP, et al:Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study; a cohort study. Lancet 358:1682-1686, 2001.
pubmed

P.90 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. p192, ライフサイエンス出版, 東京, 2009

2) 0'Brien E, Asmar R, Beilin L, et al:European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 21:821-848, 2003.

3) Pickering TG, Hall JE, Appel LJ, et al:Recommendations for blood pressure measurement in humans and experimental animals. Part 1:Blood pressure measurement in humans. A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 45:142-161, 2005.

4) Takishita S, Touma T, Kawazoe N, et al:Usefulness of leg-crossing for maintaining blood pressure in a sitting position in patients with orthostatic hypotension-case reports. Angiology 41:421-425, 1991.

5) Netea RT, Lenders JWM, Smits P, et al:Influence of body and arm position on blood pressure readings; an overview. J Hypertens 21:237-241, 2003.

6) Lane D, Beevers M, Barnes N, et al:Inter-arm differences in blood pressure; when are they clinically significant? J Hypertens 20:1089-1095, 2002.
pubmed

7) Beevers G, Lip GYH, 0:Brien E:ABC of hypertension; blood pressure measurement, part I-sphygmomanometry; factors common to all techniques. Br Med J 322:981-985, 2001.

8) Pickett CA, Jackson JL, Hemann BA, et al:Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction; meta-analysis. Lancet 371:1587-1594, 2008.
pubmed

P.95 掲載の参考文献

1) Cuspidi C, et al:Prevalence of target organ damage in treated hypertensive patients; different impact of clinic and ambulatory blood pressure control. J Hypertens 18 (6):803-809, 2000.
pubmed

2) Shintani Y, et al:Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration; the Ohasama study. J Hypertens 25 (8):1704-1710, 2007.
pubmed

3) Staessen JA, et al:Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282 (6):539-546, 1999.
pubmed

4) Verdecchia P, et al:Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol 39 (5):878-885, 2002.
pubmed

5) Verdecchia P, et al:Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81 (2):528-536, 1990.
pubmed

6) Shimada K, et al:Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 10 (8):875-878, 1992.
pubmed

7) Castelpoggi CH, et al:A blunted decrease in nocturnal blood pressure is independently associated with increased aortic stiffness in patients with resistant hypertension. Hypertens Res 32 (7):591-596, 2009.
pubmed

8) Boggia J, et al:Prognostic accuracy of day versus night ambulatory blood pressure; a cohort study. Lancet 370 (9594):1219-1229, 2007.
pubmed

9) Kario K, et al:Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives; a prospective study. Circulation 107 (10):1401-1406, 2003.
pubmed

10) Metoki H, et al:Prognostic significance for stroke of a morning pressure surge and a nocturnal blood pressure decline; the Ohasama study. Hypertension 47 (2):149-154, 2006.

11) Kario K, et al:Morning blood pressure surge and hypertensive cerebrovascular disease; role of the alpha adrenergic sympathetic nervous system. Am J Hypertens 17 (8):668-675, 2004.
pubmed

12) Marfella R, et al:Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque; role of ubiquitin-proteasome activity. Hypertension 49 (4):784-791, 2007.
pubmed

13) Rizzoni D, et al:Morning rise of blood pressure and subcutaneous small resistance artery structure. J Hypertens 25 (8):1698-1703, 2007.
pubmed

14) Pierdomenico SD, et al:Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens 22 (8):842-847, 2009.
pubmed

15) Zakopoulos NA, et al:Time rate of blood pressure variation is associated with increased common carotid artery intima-media thickness. Hypertension 45 (4):505-512, 2005.
pubmed

16) Zakopoulos NA, et al:Impact of the time rate of blood pressure variation on left ventricular mass. J Hypertens 24 (10):2071-2077, 2006.

17) Manios E, et al:Time rate of blood pressure variation is associated with impaired renal function in hypertensive patients. J Hypertens 30:2009.

18) 日本高血圧学会:家庭血圧測定条件設定の指針. ライフサイエンス出版, 東京, 2003,

19) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

20) Stergiou GS, et al:Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension. Am J Hypertens 20 (6):616-621, 2007.
pubmed

21) Gaborieau V, Delarche N, Gosse P:Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home; correlation with target organ damage. J Hypertens 26 (10):1919-1927, 2008.
pubmed

22) Ohkubo T, et al:Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement; a population-based observation in Ohasama, Japan. J Hypertens 16 (7):971-975, 1998.

23) Bobrie G, et al:Cardiovascular prognosis of " masked hypertension " detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 291 (11):1342-1349, 2004.
pubmed

24) Fagard RH, C. Van Den Broeke, P. De Cort:Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens 19 (10):801-807, 2005.

25) Kario K, et al:Morning hypertension; the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res 29 (8):581-587, 2006.
pubmed

26) Asayama K, et al:Prediction of stroke by home " morning " versus " evening " blood pressure values; the Ohasama study. Hypertension 48 (4):737-743, 2006.
pubmed

27) Matsui Y, et al:Association between the morning-evening difference in home blood pressure and cardiac damage in untreated hypertensive patients. J Hypertens 27 (4):712-720, 2009.
pubmed

28) Parati G, Omboni S, Bilo G:Why Is Out-of-Office Blood Pressure Measurement Needed? Home Blood Pressure Measurements Will Increasingly Replace Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Hypertension. Hypertension 54:181-187, 2009.

29) Ohira T, et al:Effects of habitual alcohol intake on ambulatory blood pressure, heart rate, and its variability among Japanese men. Hypertension 53 (1):13-19, 2009.
pubmed

30) Nakashita M, et al:Influence of Alcohol Intake on Circadian Blood Pressure Variation in Japanese Men; The Ohasama Study. Am J Hypertens 22 (11):1171-1176, 2009.
pubmed

31) Muxfeldt ES, et al:Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 8 (5):181-185, 2003.
pubmed

32) Hermida RC, et al:Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51 (1):69-76, 2008.
pubmed

P.101 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン (JSH 2009), ライフサイエンス出版, 東京, 2009.

2) Lewington S, Clarke R, Qizilbash N, et al:Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality; a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002.
pubmed

3) Whelton PK, He J:Blood pressure reduction. Clinical Trials in Cardiovascular Disease; A Companion to Braunwald's Heart Disease, Hennekens CH (ed), pp341-359, WB Saunders, Philadelphia, 1999.

4) Lever AF, Ramsay LE:Treatment of hypertension in the elderly. J Hypertens 13:571-579, 1995.
pubmed

P.107 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):二次性高血圧. 高血圧治療ガイドライン2009, pp97-112, ライフサイエンス出版, 東京, 2009.

2) Anderson GH, Blakeman N, Streeten DH:The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12:609-615, 1994.
pubmed

3) 尾前照雄:高血圧症の病態と予後. 日内会誌74:401-415, 1985.

4) Nishikawa T, Saito J, Omura M:Prevalence of primary aldosteronism; should we screen for primary aldosteronism before treating hypertensive patients with medication? Endocr J 54:487-495, 2007.
pubmed

5) Williams JS, Williams GH, Raji A, et al:Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalemia. J Hum Hypertens 20:129-136, 2006.
pubmed

6) Kimura G:Glomerular function reserve and sodium sensitivity. Clin Exp Nephrol 9:102-113, 2005.
pubmed

7) Kimura G:Clinical pathology and treatment of rennin-angiotensin system 2. Chronic kidney disease and the rennin-angiotensin system. Intern Med 46:1295-1298, 2007.

8) Olin JW, Piedmonte MR, Young JR, et al:The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 122:833-838, 1995.
pubmed

9) 副島秀久, 池上圭一, 町田二郎, ほか:腎血管性高血圧症に対する治療法の変遷と予後. 日泌尿会誌 81:902-909, 1990.

10) Nishimura M, Uzu T, Fujii T, et al:Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33:261-266, 1999.
pubmed

P.113 掲載の参考文献

1) 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462-1536, 2007.

2) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. pp49-53, ライフサイエンス出版, 東京, 2009.

3) Sano M, Minamino T, Komuro I, et al:p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444-448, 2007.
pubmed

4) Verdecchia P, Carini G, Circo A, et al:Left ventricular mass and cardiovascular morbidity in essential hypertension. The MAVI study. J Am Coll Cardiol 38:1829-1835, 2001.
pubmed

5) Sokolow M, Lyon TP:The ventricular complex in right ventricular hypertrophy as obtained by unipolar precordial limb leads. Am Heart J 38:273-294, 1949.
pubmed

6) Mervin J, Goldman MD:図解心電図学. 第12版, pp89-99, 金芳堂, 京都, 2001.

7) 松崎益徳, 吉川純一, ほか:臨床心臓病学. 第1版, pp346-370, 文光堂, 東京, 2006.

8) Zipes DP, Petter L Bonow RO:BRAUNWALD'S HEART DISEASE; A Textbook of Cardiovascular Medicine. 7th ed, pp967-968, Elsevier Saunders, Philadelphia, 2005.

9) OH JK, Seward JB, Tajik AJ:The Echo Manual. 3rd ed, pp256-267, Lippincott Williams & Wilkins, Rochester, 2007.

10) 中谷敏, 吉川純一, 笠貫宏, ほか:新.心臓病診療プラクティス 1. 心エコー図で診る. 第1版, pp2-17, 文光堂, 東京, 2004.

11) 日本超音波検査学会 (監):心臓超音波テキスト. 第1版, pp135-144, 医歯薬出版, 東京, 2001.

12) Nagueh SF, Middleton KJ, Kopelen HA, et al:Doppler tissue imaging; a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30:1527-1533, 1997.
pubmed

13) Budoff MJ, Naser A, Mao SS, et al:Determination of Left Ventricular Mass on Cardiac Computed Tomographic Angiography. Acad Radiol 16:726-732, 2009.

14) Myerson SG, Bellenger NG, Pennell DJ:Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance. Hypertension 39:750-755, 2002.
pubmed

P.122 掲載の参考文献

1) Toyoda K, Okada Y, Jinnouchi J, et al:High blood pressure in acute ischemic stroke and underlying disorders. Cerebrovasc Dis 22:355-361, 2006.
pubmed

2) 豊田一則:高血圧患者から脳卒中ハイリスク患者をいかに選別するか. 血圧9:879-883, 2002.

3) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧の疫学. 血圧測定と臨床評価. 高血圧治療ガイドライン2009, ppl-23, ライフサイエンス出版, 東京, 2009.

4) 中村麻子, 矢坂正弘, 崎間洋邦, ほか:くりかえす一過性黒内障に血行力学機序が推定された内頸動脈高度狭窄の一例. 臨床神経学47 (4):147-150, 2007.

5) 健康日本21企画検討会, 健康日本21計画策定検討会, 健康日本21:21世紀における国民健康づくり運動について; 健康日本21企画検討会.健康日本21計画策定検討会報告書. p177, 健康.体力づくり事業財団, 東京, 2000.

6) 岡田靖:高血圧性脳症. 総合臨床57 (増刊):552-553 2008.

7) Cooper LS, Wrong TY, Klein R, et al:Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction; the Atherosclerosis Risk in Communities Study. Stroke 37:82-86, 2006.

8) Wolf PA, et al:Asymptomatic carotid bruit and risk of stroke. The Framingham study. JAMA 2451:1442-1445, 1981.

9) 大坪亮一, 岡田靖:高血圧診療における超音波診断法. 血圧:384-387, 2008.

10) Takada J, lbayashi S, Ooboshi H, et al:Valsartan improves the lower limit of cerebral autoregulation in rats. Hypertens Res 29:621-626, 2006.

11) Ueda K, Omae T, Hasuo Y, et al:Prognosis and outcome of elderly hypertensive in a Japanese community; Results from a long-term prospective study. J Hypertension 6:991-997, 1988.

12) Yasaka M, Yamaguchi T, Shichiri M:Distribution of atherosclerosis and risk factor in atherothrombotic occlusion. Stroke 24:206-211, 1993.
pubmed

13) Sato S, Uehara T, Toyoda K, et al:Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan. The SUMO study. Stroke 40:30-34, 2009.

14) Toyoda K, Fujimoto S, Kamouchi M, et al:Acute blood pressure levels and neurological deterioration in different subtypes of ischemic stroke. Stroke 40:2585-2588, 2009.
pubmed

15) 岡田靖:頸部頸動脈狭窄症の内科治療. 医学のあゆみ228:809-815, 2009.

16) 脳ドックの新ガイドライン作成委員会 (編):脳ドックのガイドライン2008. 響文社, 札幌, 2008.

17) Shinkawa A, Ueda K, Kiyohara Y, et al:Silent brain infarction in a community-based autopsy series in Japan; The Hisayama Study. Stroke 26:380-385, 1995.

18) Fukuda H, et al:Differences between treated and untreated hypertensive subjects in the extent of periventricular hyperintensitiea observed on brain MRI. Stroke 26:1593-1597, 1995.
pubmed

19) Kato H, et al:Silent crebral microbleeds on T2*-weighted MRI; correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 33:1536-1540, 2002.

P.131 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

2) Mancia G, De Backer G, Dominiczak A, et al:Management of Arterial Hypertension of the European Society of Hypertension. 2007 Guidelines for the Management of Arterila Hypertension. J Hypertens 25:1105-1187, 2007.

3) de Zeeuw D, et al:Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 17:2100-2105, 2006.
pubmed

4) Ibsen H, Olsen MH, Lindholm LH, et al:Reduction in Albuminuria translates to reduction in cardiovascular events in hypertensive patients. Hypertension 45:198-202, 2005.
pubmed

5) Gerstein HC, et al:Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001.
pubmed

6) Dinneen SF, et al:The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus. Arch Intern Med 157:1413-1418, 1997.
pubmed

7) Adler Al, et al; on behalf of the UKPDS Group:Development and progression of nephropathy in type 2 diabetes; The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232, 2003.

8) Irie F, et al:The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69:1264-1271, 2006.
pubmed

9) Hallan Sl, et al:Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 20:1069-1077, 2009.

10) Furuki K, Adachi H, lmaizumi T, et al:Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery; an epidemiological study. Atherosclerosis 191:206-210, 2007.

11) Tatematsu S, Hayashi K, Saruta T, et al:Role of nitric oxide-producing and-degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 18:741-749, 2007
pubmed

12) Sakata K, Kumagai H, Saruta T, et al:Potentiated sympathetic nervous and renin-angiotensin systems reduce nonlinear correlation between sympathetic activity and blood pressure in conscious spontaneously hypertensive rats. Circulation 106:620-625, 2002.
pubmed

13) Wakino S, Hayashi K, Saruta T, et al:Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydolase in rats. Hypertens Res 28:255-262, 2005.
pubmed

14) Nieuwdorp M, et al:The endothelial glycocalyx; a potential barrier between health and vascular disease. Curr Opin Lipidol 16:507-511, 2005.
pubmed

15) Satchell SC, et al:What is the mechanism of microalbuminuria in diabetes; a role for the glomerular endothelium? Diabetologia 51:714-725, 2008.
pubmed

16) Nieuwdorp M, et al:Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 55:1127-1132, 2006.
pubmed

17) de Zeeuw D, Shahinfar S, Brenner BM, et al:Albuminuria, a therapeuric target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921-927, 2004.

18) de Zeeuw D, Remuzzi G, Parving H-H, et al:Proteinuria, a target for protection in patients with type 2 diabetic nephropathy; Lessons from RENAAL. Kidney Int 65:2309-2320, 2004.
pubmed

19) Araki S, Haneda M, Kashiwagi A, et al:Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 56:1727-1730, 2007.
pubmed

20) Saruta T, Hayashi K, Nakao K, et al:Effect of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease; subanalysis of the CASE-J Study. Hypertension Research 32:505-512, 2009.

P.140 掲載の参考文献

1) Mannnami T, et al:Potential of Carotid Enlargement as a Useful Indicator Affected by High Blood Pressure in a Large General Population of a Japanese City. Stroke 31:2958-2965, 2000.

2) Yasaka M, et al:Ultrasonic evaluation of the site of carotid axis occlusion in patients with acute carotidembolic stroke. Stroke 23:420-422, 1992.

3) Koga M, et al:Diagnosis of internal carotid artery stenosis greater than 70% with power Doppler duplex sonography. AJNR 22:413-417, 2001.
pubmed

4) Saito K, et al:Vertebral Artery Occlusion in Duplex Color-Coded Ultrasonography. Stroke 35:1068-1072, 2004.
pubmed

5) Todo K, Watanabe M, et al:Imaging of distal interanal carotid artery by ultrasonography with a 3.5-MHz convex probe. Stroke 33:1792-1794, 2002.

P.147 掲載の参考文献

1) 松岡秀洋, 今泉勉:心血管病診療のエクセレンス; 高血圧. 日本医師会雑誌 (生涯教育シリーズ 74) 137:S102-S113, 2008.

2) 松岡秀洋:血管機能を高血圧診療に活かす. 高血圧診療のコツと落とし穴, 島田和幸 (監), pp34-35, 中山書店, 東京, 2004

3) Matsuoka H:Endothelial dysfunction associated with oxidative stress in human. Diabetes Res Clin Pract 54 (Suppl 2):S65-S72, 2001.

4) 松岡秀洋:動脈硬化と血管内皮機能.Vascular Lab 2:25-33, 2005.

5) 松岡秀洋:血管内皮障害と治療効果; 高血圧. 治療学38:39-44, 2004.

6) Cohn JN, Quyyumi AA, Hollenberg NK, et al:Surrogate Markers for Cardiovascular Disease; Functional Markers. Circulation 109:IV-31-IV-46, 2004.

7) 松岡秀洋:血中マーカー. Mebio 24:76-81, 2007.
Medical*Online

8) Tardif JC, Heinonen T, Orloff D, et al:P. Vascular Biomarkers and Surrogates in Cardiovascular Disease. Circulation 113:2936-2942, 2006.

9) Matsuoka H:Post-prandial microvascular dysfunction. Circulation Journal 73:1399-1400, 2009.
pubmed

10) Benjamin N, Calver A, Collier J, et al:Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25 (5):918-923, 1995.
pubmed

11) 松岡秀洋, 植田真一郎, 東幸仁, ほか:心血管病サロゲートマーカーとしてのflow-mediated vasodilation測定とその標準化案. 臨床薬理38:305-309, 2007.

12) Inoue T, Matsuoka H, Node K, et al:Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens Res 31 (12):2105-2113, 2008.
pubmed

13) 松岡秀洋:内皮機能. 冠動脈疾患の予防戦略,代田浩之 (編), pp162-165, 中山書店, 東京, 2006.

14) 松岡秀洋:生理的血管傷害因子としての意義. Arterial Stiffnessの臨床-動脈壁硬化とPWV, 西沢良記 (編), pp57-64, メディカルレビュー社, 大阪, 2002.

15) 松岡秀洋:血管の老化のメカニズム. モダンフィジシャン 24:1667-1669, 2004.

16) 松岡秀洋:動脈硬化サロゲートマーカーのありかた.循環器科61:103-108, 2007.

P.151 掲載の参考文献

1) Mukoyama M, Nakao K, Hosoda K, et al:Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87:1402-1412, 1991.
pubmed

2) Maisel AS:Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension. Cardiovasc Drugs Ther 23:317-326, 2009.
pubmed

3) 米田孝司, 佐藤清:BNP検査とNT-proBNP検査の使い分け. 検査と技術 9:842-847, 2008.

4) Koren MJ, Devereux RB, Casale PN, et al:Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345-352, 1991.
pubmed

5) Seki S, Tsurusaki T, Kasai T, et al:Clinical significance of B-type natriuretic Peptide in the assessment of untreated hypertension. Circ J 72:770-777, 2008.
pubmed

6) Suzuki M, Hamada M, Yamamoto K, et al:Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 25:669-676, 2002.
pubmed

7) Olsen MH, Wachtell K, Nielsen OW, et al:N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension; a LIFE substudy. J Hypertens 24:1531-1539, 2006.
pubmed

8) Nagaya N, Nishikimi T, Okano Y, et al:Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31:202-208, 1998.

9) Andreassen AK, Wergeland R, Simonsen S, et al:N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 98:525-529, 2006.

10) Reesink HJ, Tulevski II, Marcus JT, et al:Brain natriuretic peptide as noninvasive marker of the severity of right ventricuiar dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 84:537-543, 2007.
pubmed

11) Levy D, Larson MG, Vasan RS, et al:The progression from hypertension to congestive heart failure. JAMA 275:1557-1562, 1996.
pubmed

12) Wang TJ, Larson MG, Levy D, et al:Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655-663, 2004.
pubmed

13) Kragelund C, Gronning B, Kober L, et al:N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352:666-675, 2005.

IV. 高血圧をどう治療するか

P.161 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009 (JSH 2009). ライフサイエンス出版, 東京, 2009.

2) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2004 (JSH 2004). ライフサイエンス出版, 東京, 2004.

3) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2000 (JSH 2000). ライフサイエンス出版, 東京, 2000.

4) 河野雄平, 安東克之, 松浦秀夫, ほか:食塩制限の必要性と減塩目標. 日本高血圧学会減塩ワーキンググループ報告, pp1-12, 日本高血圧学会, 東京, 2006

5) 河野雄平, 土橋卓也, 松浦秀夫, ほか:高血圧管理における食塩摂取量の評価. 日本高血圧学会減塩ワーキンググループ報告, pp13-23, 日本高血圧学会, 東京, 2006.

6) 松浦秀夫, 中東教江:高血圧患者さんのための減塩食レシピ食塩1日6グラム. 日本高血圧学会減塩ワーキンググループ報告, pp1-47, 日本高血圧学会, 東京, 2006.

7) 平成20年国民健康.栄養調査結果の概要について[Internet]. 東京, 厚生労働省, 2009年11月 http://www.mhlw.go.jp/houdou/2009/11/d1/h1109-1b.pdf (2010年2月17日確認).

8) 日本高血圧学会:食事 (減塩.肥満対策). 高血圧専門医ガイドブック, 第1版, 日本高血圧学会 (編), pp70-75, 診断と治療社, 東京, 2009.

9) Ohta Y, Tsuchihashi T, Onaka U, et al:Long-term compliance with salt restriction in Japanese hypertensive patients. Hypertens Res 28:953-957, 2005.
pubmed

10) Appel LJ, Moore TJ, Obarzanek E, et al:A clinical trial of the effects of dietary patterns on blood pressure; DASH Collaborative Research Group. N Engl J Med 336:1117-1124, 1997.

11) Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group:Effects of on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344:3-10, 2001.

12) Ueshima H, Stamler J, Elliott P, et al; INTERMAP Research Group:Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure; INTERMAP study. Hypertension 50:313-319, 2007.

13) Iso H, Kobayashi M, Ishihara J, et al:Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese; the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 113:195-202, 2006.
pubmed

14) Lichtenstein AH, Appel LJ, Brands M, et al:American Heart Association Nutrition Committee:Diet and lifestyle recommendations revision 2006; a scientific statement from the American Heart Association Nutrition Committee. Circulation 114:82-96, 2006.
pubmed

15) 食品安全情報:分野別施策; 食品中の化学物質; 魚介類に含まれる水銀. [Internet] 厚生労働省, 東京, 2005年11月2日. http://www.mhlw.go.jp/topics/bukyoku/iyaku/syoku-anzen/suigin/index.html (2010年2月17日確認).

16) Neter JE, Stam BE, Kok FJ, et al:Influence of weight reduction on blood pressure; a mete-analysis of randomized controlled trials. Hypertension 42:878-884, 2003.

17) Dickinson HO, Mason JM, Nicolson DJ, et al:Lifestyle interventions to reduce raised blood pressure; a systematic review of randomized controlled trials. J Hypertens 24:215-233, 2006.
pubmed

18) Shaper AG, Wannamethee G, Walker M:Physical activity, hypertension, and risk of heart attack in men without evidence of ischemic heart disease. J Human Hypertens 8:3-10, 1994.
pubmed

19) 健康づくりのための運動指針2006～生活習慣病予防のために～<エクササイズガイド2006>. [Internet]. 厚生労働省, 東京, 2006年7月30日 http://www.mhlw.go.jp/bunya/kenkou/undou01/pdf/data.pdf (2010年2月17日確認).

20) 日本高血圧学会:運動.禁煙.高血圧専門医ガイドブック, 第1版, 日本高血圧学会 (編), pp76-81, 診断と治療社, 東京, 2009.

21) Nakamura K, Okamura T, Hayakawa T, et al:NIPPON DATA 90 Research Group:The proportion of individuals with alcohol-induced hypertension among total hypertensives in a general Japanese population; NIPPON DATA 90. Hypertens Res 30:663-668, 2007.

22) Krijnen P, van Jaarsveld BC, Steyerberg EW, et al:A clinical prediction rule for renal artery stenosis. Ann Intern Med 129:705-711, 1998.
pubmed

23) Miyatake N, Wada J, Kawasaki Y, et al:Relationship between metabolic syndrome and cigarette smoking in the Japanese population. Intern Med 45:1039-1043, 2006.
pubmed

24) 松岡博昭, 瀧下修一:禁煙宣言[Internet]. 日本高血圧学会, 東京, 2007. 2007年10月26日 http://www.jpnsh.org/news/tabaccocontrol.pdf (2010年2月17日確認).

25) 禁煙治療のための標準手順書第3版, [Internet] 日本循環器学会, 日本肺癌学会, 日本癌学会, 京都, 2008年 4月, http://www.j-circ.or.jp/kinen/anti_smoke_std/anti_smoke_std_rev3.pdf (2010年2月17日確認).

26) Whelton PK, Appel LJ, Espeland MA, et al:Sodium reduction and weight loss in the treatment of hypertension in older persons; a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 279:839-846, 1998.

P.171 掲載の参考文献

1) Shekelle PG, Ortiz E, Rhodes S, et al:Validity of the Agency for Healthcare Research and Quality clinical practice guidelines; how quickly do guidelines become outdated? JAMA 286:1461-1467, 2001.
pubmed

2) Mancia G, De Backer G, Dominiczak A, et al:2007 Guidelines for the Management of Arterial Hypertension; The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007.

3) Turnbull F:Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events; results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003.
pubmed

4) Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al:Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25:951-958, 2007.
pubmed

5) Staessen JA, Wang JG, Thijs L:Cardiovascular prevention and blood pressure reduction; aquantitative overview updated until l March 2003. J Hypertens 21:1055-1076, 2003.

6) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Diuretic versus alpha-blocker as first-step antihypertensive therapy; final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42:239-246, 2003.

7) Pickering TG, Levenstein M, Walmsley P:Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. Am J Hypertens 7:844-847, 1994.

8) Kario K, Pickering TG, Hoshide S, et al:Morning blood pressure surge and hypertensive cerebrovascular disease; role of the alpha adrenergic sympathetic nervous system. Am J Hypertens 17:668-675, 2004.
pubmed

9) Kario K, Matsui Y, Shibasaki S, et al:An alpha-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension; the Japan Morning Surge-1 Study. J Hypertens 26:1257-1265, 2008.
pubmed

10) Shibasaki S, Eguchi K, Matsui Y, et al:Adrenegic blockade improved insuiin resistance in patients with morning hypertension; the Japan Morning Surge-1 Study. J Hypertens 27:1252-1257, 2009.

11) Dahlof B, Sever PS, Poulter NR, et al:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA); a multicentre randomised controlled trial. Lancet 366:895-906, 2005.
pubmed

12) Lindholm LH, Carlberg B, Samuelsson O:Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553, 2005.
pubmed

13) Bangalore S, Sawhney S, Messerli FH:Relation of Beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52:1482-1489, 2008.
pubmed

14) Hermida RC, Ayala DE, Fernandez JR, et al:Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51:69-76, 2008.
pubmed

15) Zhang R, Witkowski S, Fu Q, et al:Cerebral hemodynamics after short-and long-term reduction in blood pressure in mild and moderate hypertension. Hypertension 49:1149-1155, 2007.

16) Julius S, Kjeidsen SE, Weber M, et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine; the VALUE randomised trial. Lancet 363:2022-2031, 2004.
pubmed

17) Modesti PA, Morabito M, Bertolozzi l, et al:Weather-related changes in 24-hour blood pressure profile; effects of age and implications for hypertension management. Hypertension 47:155-161, 2006.

18) Turnbull F, Neal B, Pfeffer M, et al:Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25:951-958, 2007.
pubmed

19) Yusuf S, Teo KK, Pogue J, et al:Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559, 2008.

20) Mann JF, Schmieder RE, McQueen M, et al:Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study); a multicentre, randomised, double-blind, controlled trial. Lancet 372:547-553, 2008.
pubmed

21) Jamerson K, Weber MA, Bakris GL, et al:Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417-2428, 2008.

P.183 掲載の参考文献

1) Lewington S, Clarke R, Qizilbash N, et al:Age-specific relevance of usual blood pressure to vascular mortality; a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002.
pubmed

2) Tozawa M, Iseki K, Iseki C, et al:Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41:1341-1345, 2003.
pubmed

3) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

4) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic; The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002.
pubmed

5) Chobanian AV, Bakris GL, Black HR, et al:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; the JNC 7 report. JAMA 289:2560-2572, 2003.
pubmed

6) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255-3264, 1991.

7) Kostis JB, Davis BR, Cutler J, et al:Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278:212-216, 1997.

8) Franse LV, Pahor M, Di Bari M, et al:Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 35:1025-1030, 2000.
pubmed

9) Franse LV, Pahor M, Di Bari M, et al:Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 18:1149-1154, 2000.
pubmed

10) Dahlof B, et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE); a randomised trial against atenolol. Lancet 359:995-1003, 2002.
pubmed

11) Dahlof B, et al:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA); a multicentre randomised controlled trial. Lancet 366:895-906, 2005.
pubmed

12) Mancia G, De Backer G, Dominiczak A, et al:2007 Guidelines for the Management of Arterial Hypertension; The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007.

13) Monmany J, Domingo P, Gomez JA, et al:Effects of long-term treatment with metoprolol and hydrochlorothiazide on plasma lipids and lipoproteins. J Intern Med 228:323-331, 1990.
pubmed

14) Verdecchia P, Reboldi G, Angeli F, et al:Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43:963-969, 2004.
pubmed

15) Shahinfar S, Simpson RL Carides AD, et al:Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 56:1879-1885, 1999.
pubmed

16) Pordy RC:Cilazapril with adjunctive hydrochlorothiazide-analysis of safety and efficacy in hypertensive patients not responding to cilazapril alone. Cardiology 86:41-48, 1995.

17) Lacourciere Y, Gagne C:Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypetension. J Hum Hypertens 7:149-152, 1993.

18) Clarke PF, Kendall R, Hornby R, et al:Captopril and hydrochlorothiazide a safe antihypertensive for use in general practice? J Clin Pharm Ther 16:361-366, 1991.
pubmed

19) Ishimitsu T, Yagi S, Ebihara A, et al:Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension. Jpn Heart J 38:831-840, 1997.

20) Hosie J, Dahlof B, Klein G:The long-term antihypertensive efficacy and safety of a new felodipine-metoprolol combination tablet. The Swedish/UK and German Study Groups. Bbod Press Suppl 1:46-50, 1993.

21) ONTARGET Investigators:Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559, 2008.

P.191 掲載の参考文献

1) Weber MA, Julius S, Kjeldsen SE, et al:Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363:2049-2051, 2004.
pubmed

2) Saito I, Kushiro T, Ishikawa M, et al:Early antihypertensive efficacy of olmesartan medoxomil. J Clin Hypertens 10:930-935, 2008.

3) Ogihara T, Kikuchi K, Matsuoka H, et al:Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 32:1-107, 2009.
pubmed

4) The ALLHAT officers and coordinators for the ALLHAT collaborative research group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981-2997, 2002.
pubmed

5) Dahlof B, Sever PS, Poulter NR, et al, for the ASCOT investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA); amulticentre randomised controlled trial. Lancet 366:895-906, 2005.

6) Jamerson K, Weber MA, Bakris GL, et al, for the ACCOMPLISH trial investigators:Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417-2428, 2008.

7) Chobanian AV:Does it matter how hypertension is controlled? NEngl J Med 359:2485-2488, 2008.

8) ONTARGET Investigators:Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559, 2008.

9) 齊藤郁夫:服薬コンプライアンスと血圧コントロール. 血圧13:1019-1025, 2006.

10) Feldman RD, Zou GY, Vandervoort MK, et al:As implified approach to the treatment of uncomplicated hypertension. A cluster randomized, controlled trial. Hypertension 53:646-653, 2009.

11) Black HR:Triple fixed-dose combination therapy. Back to the past. Hypertension 54:19-22, 2009.

12) Elliot WJ, Grimm RH:Using diuretics in practice-One opinion. J Clin Hypertens (Greenwich) 10:856-862, 2008.

13) Wright JT JR, et al:ALLHAT findings revisited in the context of subsequent analyses, other trials and meta-analyses. Arch Intern Med 169:832-842, 2009.
pubmed

14) Chapman N, Chang CL, Dahlof B, et al, on behalf of the ASCOT Investigators:Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipid in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 118:42-48, 2008.

15) 齊藤郁夫, 小林慎, 猿田享男:医療経済の視点からみた日本の高血圧治療. Prog Med 29:376-385, 2009.
Medical*Online

16) Heidenreich PA, Davis BR, Cutler JA, et al:Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension; an analysis of the antihypertensive and Iipid-lowering treatment to prevent heart attack trial (ALLHAT). JGen Intern Med 23:509-516, 2008.

17) Lindgren P, Buxton M, Kahan T, et al, on behalf of the ASCOT trial investigators:Economic evaluation of ASCOT-BPLA antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart 94:e4-e9, 2008.

18) Montgomery AA, et al:The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension; a Markov decision analysis. J Hypertens 21:1753-1759, 2003.
pubmed

19) Saito l, Kobayashi M, Matsushita Y, Saruta T:Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan. Jpn Med Assoc J 48:574-585, 2005.

20) Saito l, Kobayashi M, Matsushita Y, et al:Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res 31:1373-1383, 2008.

P.197 掲載の参考文献

1) 尾鷲登志美, 上島国利:コンプライアンスからアドヒアランスへ月刊薬事50:373-376, 2008.

2) 芦田映直:薬物療法服薬指導. 日本臨床 64 (増刊号6):276-280, 2006.

3) 斉藤郁夫:服薬コンプライアンスと血圧コントロール. 血圧13:1019-1025, 2006.

4) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

5) Burnier M, Schneider MP, Chiolero A, et al:Electronic compliance monitoring in resistant hypertension; the basis for rational therapeutic decisions. J Hypertens 19:335-341, 2001.

6) 上島国利, 尾鷲登志美, 高橋太郎, ほか:薬物アドヒアランス. 精神神経学雑誌107:696-703, 2005.

7) Mancia G, De Backer G, Dominiczak A, et al:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 25:1105-1187, 2007.

8) Dezii CM:Aretrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 9 (Suppl 9):2-6, 2000.

9) Ashida T, Sugiyama T, Okuno S, et al:Relationship between home blood pressure measurement and medication compliance and name recognition of antihypertensive drugs. Hypertens Res 23:21-24, 2000.
pubmed

P.204 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

2) 日本脳卒中学会医療向上.社会保険委員会, rt-PA (アルテプラーゼ) 静注療法指針部会:rt-PA (アルテプラーゼ) 静注療法適正治療指針. 日本脳卒中学会ホームページ (http:/www.jsts.gr.jp), 東京, 2005.

3) Adams Jr HP, del Zippo G, Alberts MJ, et al:Guidelines for early management of adults with ischemic stroke. Stroke 38:1655-1711, 2007.

4) Potter JF, Robinson TG, Ford GA, et al:Controlling hypertension and hypotension immediately post-stroke (CHHIPS); a randomized, placebo-controlled, double-blind pilot trial. Lancet Neurol 8:48-56, 2009.
pubmed

5) Schrader J, Luders S, Kulschewski A, et al:The ACCESS study; evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34:1699-1703, 2003.
pubmed

6) Broderick J, Connoily S, Feldmann E, et al:Guidelines for the management of spontaneous intracerebral hemorrhage in adults. 2007 Update. A guideline from the American Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38:2001-2023, 2007.

7) Anderson CS, Huang Y, Wang JG, et al:Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT); a randomized pilot trial. Lancet Neurology 7:391-399, 2008.
pubmed

8) Bederson JB, Connolly ES, Batjer Jr HH, et al:Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association. Stroke 40:994-1025, 2009.

9) Wijdicks EF, Vermeulen M, Murray GD, et al:The effect of treating hypertension following aneurismal subarachnoid hemorrhage. Clin Neurol Neurosurg 92:111-117, 1990.

10) Fujii Y, Takeuchi S, Sasaki O, et al:Ultra-early rebleeding in spontaneous subarachnoid hemorrhage. J Neurosurg 84:35-42, 1996.
pubmed

11) Ohkuma H, Tsurutani H, Suzuki S, et al:Incidence and significance of early aneurismal rebleeding before neurosurgical or neurological management. Stroke 32:1176-1180, 2001.
pubmed

12) Stormelli SA, French JD:Subarachnoid hemorrhage; factors in prognosis and management. J Neurosurg 21:769-780, 1964.

13) Naidech AM, Janjua N, Kreiter KT, et al:Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. Arch Neurol 62:410-416, 2005.
pubmed

14) Hata J, Tanizaki Y, Kiyohara Y, et al:Ten year recurrence after first ever stroke in a Japanese community; the Hisayama study. J Neurol Neurosurg Psychiatry 76 (3):368-372, 2005.

15) Steg PG, Bhatt DL, Wilson PWF, et al:for the REACH Registry Investigators. One-Year Cardiovascuiar Event Rates in Outpatients With Atherothrombosis. JAMA 297:1197-1206, 2007.

16) Irie K, Yamaguchi T, Minematsu K, et al:The J-curve phenomenon in stroke recurrence. Stroke 24:1844-1849, 1993.

17) PROGRESS Collaborative Group:Randomized trial of a perindopril-based blood-pressure lowering region among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001.
pubmed

18) Arima H, Chalmers J, Woodward M, et al:Lower target blood pressure are safe and effective for the prevention of recurrent stroke; the PROGRESS trial. J Hypertens 24:1201-1208, 2006.

19) Mancia G, de Backer G, Dominiczak A, et al:2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of cardiology (ESC). J Hypertens 25:1105-1187, 2007.

20) Schrader J, Luders S, Kulschewski A, et al:Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218-1226, 2005.
pubmed

21) Yusuf S, Diener HC, Sacco RL, et al:Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1-13, 2008.
pubmed

22) Sacco RL Adams R, Albers G, et al:Guideline for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. A Statement for Healthcare Professionals From thew American Heart Association/American Stroke Association Council on Stroke. Stroke 37:577-617, 2006.

23) Rothwell PM, Howaed SC, Spence JD, for the Carotid Endarte 3 rectomy Trialists:Collaboration:Relation-ship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke 34:2583-2592, 2003.

24) Turan TN, Cotsonis G, Lynn MJ, et al, for the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation 115:2969-2975, 2007.
pubmed

P.213 掲載の参考文献

1) 日本高血圧学会ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

2) 甲斐久史, 今泉勉:臓器障害や合併症を有する高血圧治療心. Cardiac Practice 20:163-168, 2009.

3) Levy D, Garrison RJ, Savage DD, et al:Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566, 1990.
pubmed

4) Klingbeil AU, Schneider M, Martus P, et al:Ameta-analysis of the effects of treatment of left ventricular mass in essential hypertension. Am J Med 115:41-46, 2003.

5) Prospective Studies Collaboration:Age-specific relevance of usual blood pressure to vascular mortality; a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002.
pubmed

6) Mochizuki S, Dahlof B, Shimizu M, et al:Jikei Heart Study group. Valsartanina Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study); arandomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369:1431-1439, 2007.

7) Ogihara T, Nakao K, Fukui T, et al:Candesartan Antihypertensive Survival Evaluation in Japan Trial Group:Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks; candesartan antihypertensive survival evaluation in Japantrial. Hypertension 51:393-398, 2008.
pubmed

8) Kondo J, Sone T, Tsuboi H, et al:Effects of low-dose angiotensin Il receptor blocker candesartanoncardio-vascular events in patients with coronary artery disease. Am Heart J 146:E20, 2003.

9) Yui Y, Sumiyoshi T, Kodama K, et al:Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group:Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease; the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 27:181-191, 2004.

10) Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators:Efficacy of perindopril in reduction of cardiovascular events among patients with stabie coronary artery disease; randomised trial (the EUROPA study). Lancet 362:782-788, 2003.
pubmed

11) Lubsen J, Wagener G, Kirwan BA, et al:Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension; The ACTION trial. J Hypertens 23:641-648, 2005.

12) Nissen SE, Tuzcu EM, Libby P, et al:Effects of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure; the CAMEROT study; a randomised trial. JAMA 292:2217-2225, 2004.
pubmed

13) Sipahi l, Tuzcu EM, Schoenhagen P, et al:Effects of normal, prehypertensive, and hypertensive blood pressure levels on progression on coronary atherosclerosis. J Am Coll Cardiol 48:833-838, 2006.

14) Messerli FH, Mancia G, Conti CR, et al:Dogma disouted. Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884-893, 2006.
pubmed

15) Thune JJ, Signorovitch J, Kober L, et al:Effects of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertens 51:48-54, 2008.

16) Hasson L, Zanchetti A, Carruthers SG, et al:Effects of intensive blood-pressure loweing and lo-dose aspirin in patients with hypertension; principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998.

17) Rosendorff C, Black HR, Cannon CP, et al:Treatment of hypertension in the prevention and management of ischemic heart disease; ascientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115:2761-2788, 2007.

18) Mancia G, De Backer G, Dominiczak A, et al:Management of Arterial Hypertension of the European Society of Hypertension. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 25:1105-1187, 2007.
pubmed

19) Pitt B, Remme W, Zannad F, et al:Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med 348:1309-1321, 2003.

20) Pitt B, Zannad F, Remme WJ, et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999.

21) Yusuf S, Pfeffer MA, Swedberg K, et al, for the CHARM investigators and committees:Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction; the CHARM-Preserved Trial. Lancet 362:777-781, 2003.
pubmed

22) Massie BM, Carson PE, McMurray JJ, et al; I-PRESERVE Investigators:lrbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456-2467, 2008.

23) The GISSI-AF Investigators:Valsartan for Prevention of Recurrent Atrial Fibrillation. N Engl J Med 360:1606-1617, 2009.
pubmed

P.220 掲載の参考文献

1) 日本腎臓学会 (編):エビデンスに基づくCKD診療ガイドライン2009. 東京医学社, 東京, 2009.

2) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン 2009. ライフサイエンス出版, 東京, 2009.

3) 伊藤貞嘉:腎障害.腎不全を有する高血圧; チャート式高血圧併用療法. pp80-81, メディカルレビュー社, 大阪, 2005.

4) Jafar TH, Stark PC, Schmid CH, et al:Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60:1131-1140, 2001.
pubmed

5) De Zeeuw, Remuzzi G, Parving HH, et al:Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy; Lessons from RENAAL. Kidney Int 65:2309-2320, 2004.
pubmed

6) Ibsen H, Olsen MH, Wachtell K, et al:Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients; losartan intervention for endpoint reduction in hypertension study. Hypertension 45 (2):198-202, 2005.
pubmed

7) lto S, Nagasawa T, Abe M, et al:Strain Vessel Hypothesis; A viewpoint for linkage of Albuminuria and Carebro-Cardiovascular Risk. Hypertens Res 32:115-121, 2009.

8) The ONTARGET Investigators:Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559, 2008.

9) Mann JF, Schmieder RE, McQueen M, et al:Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study); amulticentre, randomised, double-blind, controlled trial; Lancet 372:547-553, 2008.
pubmed

10) 伊藤貞嘉 (編著):二次性高血圧. メディカルレビュー社, 大阪, 2003.

P.227 掲載の参考文献

1) Estacio RO, Jeffers BW, Hiatt WR, et al:The effects of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998.
pubmed

2) Tatti P, Pahor M, Byington RP, et al:Outcome results of the Fosinpril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998.
pubmed

3) Bakris GL Toto RD, McCullough PA, et al:Effects of different ACE inhibitor combinations on albuminuria; results of the GUARD study. Kidney Int 73 (11):1303-1309, 2008.
pubmed

4) Jamerson K, Weber MA, Bakris GL et al:Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (23):2417-2428, 2008.

5) Fioretto P, Steffes MW, Sutherland DE, et al:Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75, 1998.
pubmed

6) Coppelli A, Giannarelli R, Buggi U, et al:Disappearance of nephrotic syndrome in type 1 diabetic patients following pancreas transplant alone. Transplantation 81:1067-1068, 2006.

7) Boffa JJ, Lu Y, Placier S, et al:Regression of renal vascular and glomerular fibrosis; role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephro 4:1132-1144, 2003.

8) Mochizuki S, Dahlof B, Shimizu M, et al:Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study); arandomized, open-label, blinded endpoint morbidity-mortality study. Lancet 369:1431-1439, 2007.

9) Ogihara T, Nakao K, Fukui T, et al:Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks; Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertention 51:393-398, 2008.

10) Fogari R, et al:Effect of valsartan on adiponectine, leptin and resistine in hypertensive obese patients. Am J Hypertens 18:196A-197A, 2005.

11) Kjeldsen SE, Julius S, Mancia G, et al:Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients; the VALUE trial. J Hypertens 24:1405-1412, 2006.

12) Elliott WJ, Meyer PM:Incident diabetes in clinical trials of antihypertensive drugs; anetwork meta-analysis. Lancet 369:201-207, 2007.

P.234 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

2) 尾前照雄:高血圧症の病態と予後. 日内会誌74:401-415, 1985.

3) 中井滋, 政金生人, 重松隆ほか:わが国の慢性透析療法の現況 (2007年12月31日現在). 日本透析医学会雑誌42:1-45, 2009.

4) Kimura G:Clinical pathology and treatment of renin-angiotensin system 2. Chronic kidney disease and the renin-angiotensin system. Intern Med 46:1295-1298, 2007.
pubmed

5) Fukuda M, Mizuno M, Yamanaka T, et al:Patients with renal dysfunction require a longer duration until blood pressure dips during the night. Hypertension 52:1155-1160, 2008.
pubmed

6) Fukuda M, Munemura M, Usami T, et al:Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 65:621-625, 2004.
pubmed

7) Usami T, Koyama K, Takeuchi O, et al:Regional variations in the incidence of end-stage renal failure in Japan. JAMA 284:2622-2624, 2000.
pubmed

8) Kimura G, Brenner BM:The renal basis for salt sensitivity in hypertension. Hypertension; Pathophysiology, Diagnosis and Management. 2nd ed, Laragh JH BB (ed), pp1569-1588, Raven Press, New York, 1995.

9) Kimura G:Glomerular function reserve and sodium sensitivity. Clin Exp Nephrol 9:102-113, 2005.
pubmed

10) Preston RA, Singer l, Epstein M:Renal Parenchymal Hypertension; current concepts of pathogenesis and management. Arch Intern Med 156:602-61 1, 1996.

11) Blythe WB:Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 5:A50-A56, 1985.
pubmed

12) Jacobson SH, Eklof O, Eriksson CG, et al:Development of hypertension and uraemia after pyelonephritis in childhood; 27 year follow up. BMJ 299:703-706, 1989.
pubmed

13) Higashihara E, Aso Y, Shimazaki J, et al:Clinical aspects of polycystic kidney disease. J Urol 147:329-332, 1992.
pubmed

14) Chapman AB, Johnson A, Gabow PA, et al:The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323:1091-1096, 1990.
pubmed

15) Kuroda S, Nishida N, Uzu T, et al:Prevalence of renal artery stenosis in autopsy patients with stroke. Stroke 31:61-65, 2000.
pubmed

16) Nakamura S, l ihara K, Matayoshi T, et al:The incidence and risk factors of renal artery stenosis in patients with severe carotid artery stenosis. Hypertens Res 30:839-844, 2007.

17) 宮城壮太, 木村玄次郎:腎血管性高血圧症. 腎と透析 (臨時増刊号):387-392, 2006.

18) 木村玄次郎:腎血管性高血圧症.今日の診断指針, 4th ed, pp982-985, 医学書院東京, 1997.

19) 木村玄次郎:腎血管性高血圧症. 高血圧症, pp44-52, 最新医学社, 大阪, 2004.

20) 木村玄次郎:腎動脈狭窄に対するカテーテル治療. Annual Review循環器, 矢崎義雄, 高本眞一, 中沢誠 (編), pp288-294, 中外医学社, 東京, 2006.

21) Bax L, Woittiez AJ, Kouwenberg HJ, et al:Stent Placement in Patients With Atherosclerotic Renal Artery Stenosis and Impaired Renal Function; A Randomized Trial. Ann Intern Med 15:840-848, 2009.

22) van Jaarsveld BC, Krijnen P, Pieterman H, et al:The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 342:1007-1014, 2000.

23) Balk E, Raman G, Chung M, et al:Effectiveness of management strategies for renal artery stenosis; a systematic review. Ann Intern Med 145:901-912, 2006.
pubmed

24) Bloch MJ, Basile J:Clinicai insights into the diagnosis and management of renovascular disease. An evidence-based review. Minerva Med 95:357-373, 2004.

25) Bloch MJ, Basile J:Diagnosis and management of renovascular disease and renovascular hypertension. J Clin Hypertens (Greenwich) 9:381-389, 2007.
pubmed

P.240 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):二次性高血圧. 高血圧治療ガイドライン2009, pp97-113, ライフサイエンス出版, 東京, 2009.

2) Chobanian AV, Bakris GL, Black HR, et al:Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (6):1206, 2003.
pubmed

3) Mancia G, De Backer G, Dominiczak A, et al:2007 Guidelines for the management of arterial hypertension; The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 (12):1462, 2007.

4) 成瀬光栄, ほか:原発性アルドステロン症の合併症と予後. 循環器科53:130-134, 2003.

5) 名和田新:厚生省特定疾患内分泌系疾患調査研究班「副腎ホルモン産生異常症」調査研究班, 平成10年度研究報告書. p11, 1999.

6) Howlett TA, Rees LH, Besser GM:Cushing's syndrome. Clin Endocrinol Metab 14 (4) 1911, 1985.

7) Fukuda I, Hizuka N, Murakami Y, et al:Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women:s Medical University. Intern Med 40 (10):987, 2001.
pubmed

8) Omura M, Saito J, Yamaguchi K, et al:Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27 (3):193, 2004.
pubmed

9) Scholz T, Eisenhofer G, Pacak K, et al:Clinical review; Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92 (4):1217, 2007.
pubmed

P.251 掲載の参考文献

1) Shores J, Berger KR, Merphy ER, et al:Progression of aortic dilation and the benefit of long-term B-adore-nergic blockde in marfan:s syndorome. N Engl J Med 330:1335-1341, 1994.

2) Brooke BS, Habashi JP, Judge DP, et al:Angiotensin II blockade and aortic-root dilation in Marfan:s syn-drome. N Engl J Med 358 (26):2787-2795, 2008.

3) Lacro RV, Dietz HC, Wruck LM, et al:Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 154 (4):624-630, 2007.
pubmed

4) Hackam DG, Thiruchelvam D, Redelmeier DA, et al:Angiotensin-converting enzyme inhibitors and aortic rupture; a population-based case-control study. Lancet 368 (9536):659-665, 2006.
pubmed

5) von Kodolitsch Y, Csosz SK, Koschyk DH, et al:Intramural hematoma of the aorta; predictors of progression to dissection and rupture. Circulation 107 (8):1158-1163, 2003.
pubmed

6) Genoni M, Paul M, Jenni R, et al:Chronic beta-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg 19 (5):606-610, 2001.

7) Takeshita S, Sakamoto S, Kitada S, et al:Angiotensin-converting enzyme inhibitors reduce long-term aortic events in patients with acute type B aortic dissection. Circ J 72 (11):1758-1761, 2008.

8) Mochizuki S, Dahlof B, Shimizu M, et al:Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study); a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369 (9571):1431-1439, 2007.

9) 小林靖, 橋本博史, ほか:大動脈炎症候群 (高安動脈炎) 診断.治療指針. 特定疾患対策研究事業. 難治性血管炎に関する調査研究, 平成11～13年度総合研究報告書. pp41-63, 2002.

10) 橋本博史, ほか:厚生省特定疾患免疫疾患調査研究班「難治性血管炎分科会」平成13年度研究報告書. pp21-25, 2002.

11) Kobayashi Y, Ishii K, Oda K, Nariai T, et al:Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med 46 (6):917-922, 2005.
pubmed

12) Toro-Salazar OH, Steinberger J, Thomas W, et al:Long-term follow-up of patients after coarctation of the aorta repair. Am J Cardiol 89 (5):541-547, 2002.

13) Murakami T, Ueno M, Takeda A, Yakuwa S, et al:Pressure wave reflection after successful balloon dilatation of aortic coarctation. Circ J 71 (11):1821-1822, 2007.
pubmed

14) Ross RD, Clapp SK, Gunther S, et al:Augmented norepinephrine and renin output in response to maximal exercise in hypertensive coarctectomy patients. Am Heart J 123 (5):1293-1299, 1992.
pubmed

15) Blaustein DA, Kumbar L Srivastava M, et al:Poiyarteritis nodosa presenting as isolated malignant hypertension. Am J Hypertens 17 (4):380-381, 2004.
pubmed

16) 黒沢美智子, 稲葉裕,小林茂人, ほか:難治性血管炎に関する調査研究班「中,小型血管炎の臨床研究分科会平成17年度研究報告書. pp137-150, 2006.

P.257 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. pp110-112, ライフサイエンス出版東京, 2009.

2) Pope JE, Anderson JJ, Felson DT:Ameta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch intern Med 153:447, 1993.

3) 本間真人, 千文, 幸田幸直, ほか:芍薬甘草湯と小柴胡湯の連用が血清カリウムに及ぼす影響. 薬学雑誌 126:973-978, 2006.

4) Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al:Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology 47:72-75, 2008.
pubmed

5) Halimi JM, Giraudeau B, Buchler M, et al:Enarapril/amlodipine combination in cyclosporine-treated renal transplant recipients; a prospective randomized trial. Clin Transplant 21:277-284, 2007.

6) 鈴木正司, 合屋忠信:EPO使用基準のガイドライン作成の調査. 平成4年度厚生科学研究腎不全医療研究事業研究報告書. pp165-172, 1993.

7) Rossouw JE, Anderson GL, Prentice RL, et al:Risks and benefits of estrogen plus progestin in healthy postmenopausai women; principal results From the Women:s Health Initiative randomized controlled trial. JAMA 288:321-333, 2002.
pubmed

P.262 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版J東京, 2009.

2) Ohta Y, Tsuchihashi T, Arakawa K, et al:Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an outpatient clinic in Fukuoka, Japan. Hypertens Res 30:1077-1082, 2007.
pubmed

3) Ohta Y, Tsuchihashi T, Miyata E, et al:Usefulness of self-monitoring of urinary salt excretion in hypertensive patients. Clin Exp Hypertens 31:690-697, 2009.
pubmed

4) 守永友希, 土橋卓也, 大田祐子, ほか:低用量および超低用量降圧利尿薬の有用性と安全性についての検討, 血圧15:997-1000, 2008.

5) Ohta Y, Tsuchihashi T, Onaka U, et al:Usefulness of a1-blocker doxazosin as a third-line antihypertensive drug. Hypertens Res 30:301-306, 2007.

6) Kario K:Obstructive sleep apnea syndrome and hypertension; ambulatory blood pressure. Hypertens Res 32:428-432, 2009.
pubmed

7) Ruttanaumpawan P, Nopmaneejumruslers C, Logan AG, et al:Association between refractory hypertension and obstructive sleep apnea. J Hypertens 27:1439-1445, 2009.
pubmed

8) Kario K:Obstructive sleep apnea syndrome and hypertension; mechanism of the linkage and 24-hblood pressure control Hypertens Res 32:537-541, 2009.

9) Friedman O, Logan AG:The price of obstructive sleep apnea-hypopnea; Hypertension and other ill effects. Am J Hypertens 22:474-483, 2009.

P.272 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

2) Arima H, Tanizaki Y, Kiyohara Y, et al:Validity of the JNC VI recommendations for the management of:hypertensionina generai popuiationof Japanese elderly; the Hisayama study. Arch Intern Med 163:361-366, 2003.

3) Lewington S, Clarke R, Qizilbash N, et al:Prospective Studies Collaboration:Age-specific relevance of usual blood pressure to vascular mortality; a meta-analysis of individual data for one million adults in61 prospective studies. Lancet 360:1903-1913, 2002.
pubmed

4) Okayama A, Kadowaki T, Okamura T, et al:The NIPPON DATA80 Research Group:Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese me (NIPPON DATA80). J Hypertens 24:459-462, 2006.

5) Liu L, Wang JG, Gong L, et al; Systolic Hypertension in China (Syst-China) Collaborative Group:Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 16:1823-1829, 1998.

6) Beckett NS, Peters R, Fletcher AE, et al:HYVET Study Group:Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887-1898, 2008.
pubmed

7) JATOS Study Group:Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 31:2115-21 27, 2008.

8) Ogihara T:Practitioner:s Trial onthe Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens 13:461-467, 2000.

9) Ogihara T, Nakao K, Fukui T, et al:The optimal target blood pressure for antihypertensive treatment in the Japanese elderly patients with high-risk hypertension; a subanalysis of Candesartan Antihypertensive Survival Evaluationin Japan (CASE-J) trial. Hypertens Res 31:1595-1601, 2008.

10) Okaishi K, Morimoto S, Fukuo K, et al:Reduction of risk of pneumonia associated with use of angiotensin-converting enzyme inhibitors in elderly inpatients. Am J Hypertens 12:778-783, 1999.
pubmed

P.279 掲載の参考文献

1) Reckelhoff JF:Gender differences in the regulation of blood pressure. Hypertension 37 (5):1199-1208, 2001.
pubmed

2) Ramsay LE, Waller PC:Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension; an overview of published series. Bmj 300 (6724):569-572, 1990.
pubmed

3) Saruta T, Suzuki H, Handa M, et al:Multiple factors contribute to the pathogenesis of hypertension in Cushing:s syndrome. J Clin Endocrinol Metab 62 (2):275-279, 1986.

4) 佐藤和雄:妊娠高血圧症候群の定義と分類. 日産婦誌56:12-13, 2004.

5) Karumanchi SA, Lindheimer MD:Preeclampsia pathogenesis; " triple a rating "-autoantibodies and antiangiogenic factors. Hypertension 51 (4):991-992, 2008.
pubmed

6) Girouard J, Giguere Y, Moutquin JM, et ai:Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension 49 (5):1056-1062, 2007.

7) Fisman EZ, Tenenbaum A, Pines A:Systemic hypertension in postmenopausal women; aclinical approach. Curr Hypertens Rep 4 (6):464-470, 2002.

8) McDonald SD, Malinowski A, Zhou Q, et al:Cardiovascular sequelae of preeclampsia/eclampsia; a systematic review and meta-analyses. Am Heart J 156 (5):91 8-930, 2008.

P.286 掲載の参考文献

1) 肥塚昌子, 桑島巌, 鈴木康子:老年者における白衣効果の検討. 日老医誌29:912-917, 1992.

2) lwao K, Mariko M, et al:Diagnostic value of electrocardiography and echocardiography for white coat hypertension in the elderly. Am J Cardiol 73:1232-1234, 1994.

3) Kuwajima l, Suzuki Y, Fuj isawa A, et al:Is white coat hypertension innocent? Structure and function of the heart in the elderly. Hypertension 22 (6):826-831, 1993.

4) Julius S, Mejia A, Jones K, et al:" White coat " versus " sustained " borderline hypertension in Tecumseh, Michigan. Hypertension 16 (6):617-623, 1990.
pubmed

5) Bidlingmeyer I, Burnier M, Bidlingmeyer M, et al:Isolated office hypertension; a prehypertensive state? J Hypertens 14 (3):327-332, 1996.

6) Verdecchia P:Short-and long-term incidence of stroke in white-coat hypertension. Hypertension 45:203-208, 2005.

7) Pickering TG, et al:Masked hypertension. Hypertension 40 (6):795-796, 2002.
pubmed

8) 猿原大和, 原田和昌, ほか:職場高血圧に関する研究. 日本医事新報4258:1-5, 2005.

9) Bobrie G, Chatellier G, NG, et al:Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 291:1342-1349, 2004.

10) AllHAT grroup:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981-2997, 2002:
pubmed

P.294 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. pp90-96, ライフサイエンス出版, 東京, 2009.

2) Manica G, De BackerG, Dominiczak, et al; The Task Force for the Management of Arterial Hypertension of European Society of Hypertension (ESH) and the European Society of Cardiology (ESC):Management of Arterial Hypertension of the European Society of Hypertension. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 25:1105-1187, 2007.

3) Fleisher LA, et al:ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Circulation 116:e418-e500, 2007.
pubmed

4) Coriat P, Richer C, Douraki T, et al:Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology 81:299-307, 1994.
pubmed

5) Bertrand M, Godet G, Meersschaert K, et al:P. Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg 92:26-30, 2001.
pubmed

6) Comfere T, Sprung J, Kumar MM, et al:Angiotensin system inhibitors in a general surgical population. Anesth Analg 100:636-644, 2005.

P.303 掲載の参考文献

1) 日本高血圧学会国血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

2) Marques-Vidal P, Tuomilehto J:Hypertension awareness, treatment and control in the community; is the rule of halves. still valid? J HumHypertens 11:21 3-220, 1997.

3) Oikawa T, Obara T, Ohkubo T, et al:J-HOME Study Group:Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measurements; the J-HOME study. J Hypertens 24:1737-1743, 2006.

4) 藤田敏郎, 寺本民生:高血圧および高脂血症の薬物療法の現状と課題; Japan Guideline Assessment Panel (J-GAP). Progress in Medicine 26 (9):2297-2306, 2006.
Medical*Online

5) Erdine S:How well is hypertension controlled in Europe. ESH scientific letter 8:No. 3, 2007.

6) Kaplan NM:Treatment of hypertension. Kaplan:S clinical hypertension, 9th ed, pp217-310, Lippincott Williams & Wilkins, Philadelphia, 2006.

7) Maxwell MH, Waks AU, Schroth PC, e al:Error in blood-pressure measurement due to incorrect cuff size in obese patients. Lancet 2 (8288):33-36, 1982.

8) Kuwajima l, Hoh E, Suzuki Y, et al:Pseudo-hypertension in the elderly. J Hypertens 8:429-432, 1990.

9) Law MR, Wald NJ, Morris JK, et al:Value of low dose combination treatment with blood pressure lowering drugs; analysis of 354 randomised trials. BMJ 326:1427, 2003.
pubmed

10) Moser M, Setaro JF:Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 355:385-392, 2006.
pubmed

V. これからの高血圧治療

P.311 掲載の参考文献

1) JSH:Japanese Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 29 Supplement:S1-S105, 2006.

2) Murakami Y, Hozawa A, Okamura T, et al:Relation of blood pressure and all-cause mortality in 180,000 Japanese participants; pooled analysis of 13 cohort studies. Hypertension 51:1483-1491, 2008.
pubmed

3) Hozawa A, Kuriyama S, Kakizaki M, et al:Attributable risk fraction of prehypertension on cardiovascular disease mortality in the Japanese population; the Ohsaki Study. Am J Hypertens 22:267-272, 2009.
pubmed

4) Harrap SB, Van der Merwe MW, Griffin SA, et al:Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 16:603-614, 1990.

5) Wu JN, Berecek KH:Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 22:139-146, 1993.
pubmed

6) Nakaya H, Sasamura H, Hayashi M, et al:Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 12:659-666, 2001.
pubmed

7) Nakaya H, Sasamura H, Mifune M, et al:Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 91:710-718, 2002.
pubmed

8) Ishiguro K, Sasamura H, Sakamaki Y, et al:Developmental activity of the renin-angiotensin system during the "critical period " modulates later L-NAME-induced hypertension and renal injury. Hypertens Res 30:63-75, 2007.
pubmed

9) Julius S, Nesbitt SD, Egan BM, et al:Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685-1697, 2006.
pubmed

10) Luders S, Schrader J, Berger J, et al:The PHARAO study; prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure; aprospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26:1487-1496, 2008.

11) Hansson L Zanchetti A, Carruthers SG, et al:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension; principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998.

12) Adler A1, Stratton IM, Neil HA, et al:Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36); prospective observational study. Bmj 321:412-419, 2000.

13) Schrier RW, Estacio RO, Esler A, et al:Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086-1097, 2002.
pubmed

14) Shimamoto K, Fuj ita T, Ito S, et al:Impact of blood pressure control on cardiovascular events in 26, 512 Japanese hypertensive patients:the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. Hypertens Res 31:469-478, 2008.

15) Peterson JC, Adler S, Burkart JM, et al:Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995.
pubmed

16) Jafar TH, Stark PC, Schmid CH, et al:Progression of chronic kidney disease; the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition; a patient-level meta-analysis. Ann Intern Med 139:244-252, 2003.
pubmed

P.316 掲載の参考文献

1) Fields LE, Burt VL Cutler JA, et al:The burden of adult hypertension in the United States 1999 to 2000; a rising tide. Hypertension 44:398-404, 2004.
pubmed

2) Lawes CM, Vander Hoorn S, Rodgers A:International Society of Hypertension; Global burden of blood-pressure-related disease, 2001. Lancet 371:1513-1518, 2008.
pubmed

3) Cargill M, Altshuler D, lreland J, et al:Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22:231-238, 1999.

4) Marth G, Yeh R, Minton M, et al:Single-nucleotide polymorphisms in the public domain; how useful are they? Nat Genet 27:371-372, 2001.
pubmed

5) Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al:Molecular basis of human hypertension; role of angiotensinogen. Cell 71:169-180, 1992.
pubmed

6) McCarthy ML Abecasis GR, Cardon LR, et al:Genome-wide association studies for complex traits; consensus, uncertainty and challenges. Nat Rev Genet 9:356-369, 2008.

7) Manolio TA, Brooks LD, Collins FS:AHapMap harvest of insights into the genetics of common disease. J Clin Invest 118:1590-1605, 2008.

8) Levy D, Ehret GB, Rice K, et al:Genome-wide association study of blood pressure and hypertension. Nat Genet. 41:677-687, 2009.
pubmed

9) Newton-Cheh C, Johnson T, Gateva V, et al:Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41:666-676, 2009.
pubmed

10) Brown MJ:Hypertension and ethnic group. BMJ 332:833-836, 2006.
pubmed

11) Katsuya T, Iwashima Y, Sugimoto K, et al:Effects of antihypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 24:463-467, 2001.
pubmed

12) Pereira TV, Nunes AC, Rudnicki M, et al:Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension; a role beyond M235T? Hypertension 51:778-783, 2008.
pubmed

13) Hunt SC, Cook NR, Oberman A, et al:Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension; trials of hypertension prevention, phase II. Hypertension 32:393-401, 1998.
pubmed

14) Svetkey LP, Moore TJ, Simons-Morton DG, et al:DASH collaborative research group:Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study. J Hypertens 19:1949-1956, 2001.

15) Lynch Al, Arnett DK, Davis BR, et al:Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment; the GenHAT study. Ann Hum Genet 71:735-745, 2007.

16) Schelleman H, Klungel OH, Witteman JC, et al:Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet 15:478-484, 2007.
pubmed

17) Padmanabhan S, Wallace C, Munroe PB, et al:Chromosome 2p shows significant linkage to antihypertensive response in the British Genetics of Hypertension Study. Hypertension 47:603-608, 2006.
pubmed

P.321 掲載の参考文献

1) Wood JM, Heusser C, Gulati N, et al:Monoclonal antibodies against human renin, Blood pressure effects in the marmoset. Hypertension 8 (7):600-605, 1986.
pubmed

2) Kokubu T, Ueda E, Fujimoto S, et al:Peptide inhibitors of the renin-angiotensin system. Nature 217 (5127):456-457, 1968.
pubmed

3) Burton J, Cody RJ Jr., Herd JA, et al:Specific inhibition of renin by an angiotensinogen analog; studies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci USA 77 (9):5476-5479, 1980.
pubmed

4) Hiwada K, Kokubu T, Murakami E, et al:Ahighly potent and long-acting oral inhibitor of human renin. Hypertension 11 (6 Pt 2):708-712, 1988.

5) Wood JM, Schnell CR, Cumin F, et al:Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 23 (2):417-426, 2005.
pubmed

6) Pilz B, Shagdarsuren E, Wellner M, et al:AIiskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46 (3):569-576, 2005.
pubmed

7) Nussberger J, Wuerzner G, Jensen C, et al:Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100); comparison with enalapril. Hypertension 39 (1):E1-E8, 2002.
pubmed

8) Gradman AH, Schmieder RE, Lins RL, et al:Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (8):1012-1018, 2005.
pubmed

9) 栗本沙:直接的レニン阻害薬; アリスキレン. BIO Clinica 22 (1):63-67, 2007.

P.326 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2004. ライフサイエンス出版, 東京, 2004.

2) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

3) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日内会誌94:188-203, 2005.

4) 平成18年国民健康.栄養調査結果の概要. http://www.mhlw.go.jp/houdou/2008/04/dl/h0430-2a. pdf

5) International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at:http://www.idf.org/webdata/docs/IDF_Meta_detfinalpdf.Accessed2009/7

6) Eguchi M, et al:Visceral Obesity in Japanese Patients with Metabolic Syndrome; Reappraisal of Diagnostic Criteria by CT scan. Hypertens Res 30:315-323, 2007.
pubmed

7) Hara K, Matsushita Y, Horikoshi M, et al:A proposal for the cutoff point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population. Diabetes Care 29:1123-1124, 2006.
pubmed

8) Miyawaki T, et al:Metabolic syndrome in Japanese diagnosed with visceral fat measurement by computed tomography. Proc. Japan Acad 81 (Ser B):471-479, 2005.

9) 竹内宏, ほか:10年間における急性心筋梗塞発症率の変化; 北海道地方都市における循環器疾患登録研究日循予防誌37:181-185, 2002.

10) 大西浩文, 齋藤重幸, 島本和明:端野.壮瞥町研究レビュー2007. THERAPEUTIC RESEACH 28:513-525, 2007.

11) Ninomiya T, et al:Impact of metabolic syndrome on the development of cardiovascular disease in general Japanese population; the Hisayama study. Stroke 38:2063-2069, 2007.
pubmed

P.332 掲載の参考文献

1) Gold MR, Siegel JE, Russell LB, et al:Cost-Effectiveness in Health and Medicine. 1st ed, Oxford Univ Press, New York, 1996.

2) National Institute for Health and Clinical Excellence (NICE):Updated guide to the methods of technology appraisal-June 2008.

3) Edelson JT, Weinstein MC, Tosteson AN, et al:Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407-413, 1990.
pubmed

4) National Institute for Health and Clinical Excellence (NICE):NICE clinical guideline 34. Hypertension. Management of hypertension in adults in primary care-June 2006. CG34 Hypertension:NICE guideline (all the recommendations)

5) 齊藤郁夫, 小林慎, 猿田享男:本態性高血圧患者に対する降圧薬治療の薬剤経済性分析. 臨床医薬19:777-788, 2003.

6) Saito l, Kobayashi M, Matsushita Y, et al:Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan. Jpn Med Assoc J 48:574-585, 2005.

7) Saito l, Fujikawa K, Saruta T:ADVANCE-Combi study group:Cost-effectiveness analysis; Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension; The adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. Hypertens Res 31:1399-1405, 2008.

8) Saito l, Kobayashi M, Matsushita Y, et al:Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res 31:1373-1383, 2008.

9) 福永英史, ほか:日本の高血圧診療に家庭血圧測定を導入した場合の費用対効果分析. 医療経済研究19:211-231, 2008.

10) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.

はじめての方へ

個人／法人会員登録のご案内